|
|
|
|
Twice-Daily ARV Treatment Better than Once-Daily for Some
Even though people living with HIV may be more likely to adhere to a Kaletra (lopinavir/ritonavir)-based treatment regimen taken once a day compared with twice a day, those with high pre-treatment viral loads may experience virologic failure faster using...
|
|
|
Replication Capacity: An Additional Measure of HIV Disease Progression?
HIVs replication capacity (RC), a measurement of the viruss fitness, may be useful for people living with HIV and their health care providers in figuring out how quickly HIV disease will progress, according to new data published in the April 1 issue of the...
|
|
|
New Treatments for HIV: Part 1
At the 17th Conference on Retroviruses and Opportunistic Infections (CROI) in San FranciscoTim Horn speaks with David Hardy, MD, from Cedars Sinai Medical Center in Los Angeles, about new HIV treatmentsincluding the drug blood level-booster, cobicistat, and the...
|
|
|
New Treatments for HIV: Part 2
At the 17th Conference on Retroviruses and Opportunistic Infections (CROI) in San FranciscoTim Horn speaks with David Hardy, MD, from Cedars Sinai Medical Center in Los Angeles, about new HIV treatmentsincluding two entry inhibitors: vicriviroc and TBR-652.
|
|
|
HIV Can Hide in Bone Marrow, Evade Treatment
HIV can infect bone marrow cells and remain hidden to avoid treatment, according to a new study reported on by The Associated Press.The study, led by Kathleen Collins, MD, of the University of Michigan, is published this week in the journal Nature Medicine....
|
|
|
Cancer Risks and HIV
At the 17th Conference on Retroviruses and Opportunistic Infections (CROI) in San FranciscoDavid Evans speaks with Michael Silverberg, PhD, from the Kaiser Permanente Division of Research in Oakland, California, about the latest research on cancer risk in...
|
|
|
HIV Treatment in Southern Africa
At the 17th Conference on Retroviruses and Opportunistic Infections (CROI) in San FranciscoDavid Evans speaks with Suzanne Ingle, from the University of Bristol in England, about factors affecting the roll out of HIV treatment in Southern Africa.7 1/2...
|
|
|
Abortion Pill for HIV Doesnt Pan Out in Study
One of the most intriguing compounds to be studied as an antiretroviral (ARV) is mifepristone, a medication sold in the United States as Mifeprex (also known as RU-486) and used to chemically induce abortions in the early stages of pregnancy.While the...
|
|
|
Stopping Tenofovir Doesnt Always Reverse Kidney Damage
Kidney damage caused by tenofovir (found in Viread, Truvada and Atripla) may not reverse itself after a year of discontinuing the drug, according to new study results published ahead of print on the website for the Journal of Acquired Immune Deficiency...
|
|
|
HIV and Cancer Risk
_ HIV and Cancer Risk.
|
